Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.

Kaneko Y, Hatano R, Hirota N, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Valleix F, Podoll T, Umezawa Y, Takao S, Iwata S, Hosono O, Taguchi T, Yamada T, Dang NH, Ohnuma K, Angevin E, Morimoto C

Open source

DOI: 10.1186/s40364-021-00273-0
Published: 2021 Mar 23
Container: Biomarker research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s40364-021-00273-0,
  title = {Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.},
  author = {Kaneko Y and Hatano R and Hirota N and Isambert N and Trillet-Lenoir V and You B and Alexandre J and Zalcman G and Valleix F and Podoll T and Umezawa Y and Takao S and Iwata S and Hosono O and Taguchi T and Yamada T and Dang NH and Ohnuma K and Angevin E and Morimoto C},
  year = {2021},
  journal = {Biomarker research},
  doi = {10.1186/s40364-021-00273-0},
  url = {https://doi.org/10.1186/s40364-021-00273-0}
}

RIS

TY  - JOUR
TI  - Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.
AU  - Kaneko Y
AU  - Hatano R
AU  - Hirota N
AU  - Isambert N
AU  - Trillet-Lenoir V
AU  - You B
AU  - Alexandre J
AU  - Zalcman G
AU  - Valleix F
AU  - Podoll T
AU  - Umezawa Y
AU  - Takao S
AU  - Iwata S
AU  - Hosono O
AU  - Taguchi T
AU  - Yamada T
AU  - Dang NH
AU  - Ohnuma K
AU  - Angevin E
AU  - Morimoto C
PY  - 2021
JO  - Biomarker research
DO  - 10.1186/s40364-021-00273-0
UR  - https://doi.org/10.1186/s40364-021-00273-0
ER  -

APA

Y, K., R, H., N, H., N, I., V, T., B, Y., J, A., G, Z., F, V., T, P., Y, U., S, T., S, I., O, H., T, T., T, Y., NH, D., K, O., E, A., & C, M. (2021). Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.. Biomarker research. https://doi.org/10.1186/s40364-021-00273-0

Source records

pubmed · retrieved 2026-09-27T12:03:25.801Z